Cancer - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols HRAS and ANAPC1	Name 1 HRas proto-oncogene, GTPase	Name2 anaphase promoting complex subunit 1	Pathway 1 SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth EPHB-mediated forward signaling Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2 Inactivation of APC/C via direct inhibition of the APC/C complex APC/C:Cdc20 mediated degradation of Cyclin B Autodegradation of Cdh1 by Cdh1:APC/C APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase APC/C:Cdc20 mediated degradation of mitotic proteins Phosphorylation of the APC/C APC-Cdc20 mediated degradation of Nek2A Separation of Sister Chromatids Senescence-Associated Secretory Phenotype (SASP) Assembly of the pre-replicative complex CDK-mediated phosphorylation and removal of Cdc6 Transcriptional Regulation by VENTX Aberrant regulation of mitotic exit in cancer due to RB1 defects Antigen processing: Ubiquitination & Proteasome degradation	Drugs 1 Hexane-1,6-Diol Trifluoroethanol Guanosine-5'-Triphosphate Guanosine-5'-Diphosphate N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE Ursolic acid	Drugs 2	Diseases 1 Penile cancer Cervical cancer Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Hepatocellular carcinoma Thyroid cancer Squamous cell carcinoma Bladder cancer	Diseases 2
Novel Novel	Symbols HRAS and RASGRP1	Name 1 HRas proto-oncogene, GTPase	Name2 RAS guanyl releasing protein 1	Pathway 1 SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth EPHB-mediated forward signaling Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2 Effects of PIP2 hydrolysis Activation of RAS in B cells Activation of RAS in B cells FCERI mediated NF-kB activation Integrin signaling Rap1 signalling RAF/MAP kinase cascade	Drugs 1 Hexane-1,6-Diol Trifluoroethanol Guanosine-5'-Triphosphate Guanosine-5'-Diphosphate N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE Ursolic acid	Drugs 2	Diseases 1 Penile cancer Cervical cancer Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Hepatocellular carcinoma Thyroid cancer Squamous cell carcinoma Bladder cancer	Diseases 2
Novel Novel	Symbols HRAS and TLR9	Name 1 HRas proto-oncogene, GTPase	Name2 toll like receptor 9	Pathway 1 SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth EPHB-mediated forward signaling Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2 PI3K Cascade Trafficking and processing of endosomal TLR Toll Like Receptor 9 (TLR9) Cascade Potential therapeutics for SARS TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation MyD88 dependent cascade initiated on endosome	Drugs 1 Hexane-1,6-Diol Trifluoroethanol Guanosine-5'-Triphosphate Guanosine-5'-Diphosphate N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE Ursolic acid	Drugs 2 Chloroquine Hydroxychloroquine ISS-1018 Golotimod CPG 10101 Tilsotolimod	Diseases 1 Penile cancer Cervical cancer Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Hepatocellular carcinoma Thyroid cancer Squamous cell carcinoma Bladder cancer	Diseases 2
Novel Novel	Symbols KRAS and SOX4	Name 1 KRAS proto-oncogene, GTPase	Name2 SRY-box transcription factor 4	Pathway 1 Signaling by moderate kinase activity BRAF mutants Paradoxical activation of RAF signaling by kinase inactive BRAF RUNX3 regulates p14-ARF RAS processing Signaling downstream of RAS mutants Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2 Deactivation of the beta-catenin transactivating complex	Drugs 1 [(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID Farnesyl diphosphate Adagrasib Sotorasib	Drugs 2	Diseases 1 Acute myeloid leukemia (AML) Oral cancer Non-small cell lung cancer Multiple myeloma Cervical cancer Kaposi's sarcoma Cholangiocarcinoma Gallbladder cancer Gastric cancer Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Ovarian cancer Hepatocellular carcinoma Thyroid cancer Squamous cell carcinoma Colorectal cancer Endometrial Cancer Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Pancreatic cancer	Diseases 2
Novel Novel	Symbols TGFBR1 and KLHL1	Name 1 transforming growth factor beta receptor 1	Name2 kelch like family member 1	Pathway 1 Downregulation of TGF-beta receptor signaling Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) SMAD2/3 Phosphorylation Motif Mutants in Cancer TGFBR2 Kinase Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer TGFBR1 LBD Mutants in Cancer UCH proteinases Ub-specific processing proteases TGFBR3 regulates TGF-beta signaling	Pathway 2	Drugs 1 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline Naphthyridine Inhibitor 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine Fostamatinib	Drugs 2	Diseases 1 Loeys-Dietz syndrome (LDS) Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)	Diseases 2
Novel Novel	Symbols TGFBR1 and DCAF12	Name 1 transforming growth factor beta receptor 1	Name2 DDB1 and CUL4 associated factor 12	Pathway 1 Downregulation of TGF-beta receptor signaling Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) SMAD2/3 Phosphorylation Motif Mutants in Cancer TGFBR2 Kinase Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer TGFBR1 LBD Mutants in Cancer UCH proteinases Ub-specific processing proteases TGFBR3 regulates TGF-beta signaling	Pathway 2	Drugs 1 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline Naphthyridine Inhibitor 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine Fostamatinib	Drugs 2	Diseases 1 Loeys-Dietz syndrome (LDS) Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)	Diseases 2
Novel Novel	Symbols TP53 and TAF1C	Name 1 tumor protein p53	Name2 TATA-box binding protein associated factor, RNA polymerase I subunit C	Pathway 1 Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PI5P Regulates TP53 Acetylation G2/M DNA damage checkpoint G2/M Checkpoints Stabilization of p53 Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional Regulation by VENTX RUNX3 regulates CDKN1A transcription Regulation of PTEN gene transcription Regulation of PTEN gene transcription Loss of function of TP53 in cancer due to loss of tetramerization ability Signaling by ALK fusions and activated point mutants Regulation of NF-kappa B signaling Zygotic genome activation (ZGA) Factors involved in megakaryocyte development and platelet production PKR-mediated signaling	Pathway 2 SIRT1 negatively regulates rRNA expression NoRC negatively regulates rRNA expression B-WICH complex positively regulates rRNA expression RNA Polymerase I Transcription Initiation RNA Polymerase I Transcription Initiation RNA Polymerase I Promoter Escape RNA Polymerase I Transcription Termination	Drugs 1 Acetylsalicylic acid Zinc Triethyl phosphate AZD 3355 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1 Chronic myeloid leukemia (CML) Breast cancer Non-small cell lung cancer Gastric cancer Adult T-cell leukemia Choriocarcinoma Esophageal cancer Glioma Pancreatic cancer Vulvar cancer Multiple myeloma Choroid plexus papilloma Ovarian cancer Hepatocellular carcinoma Squamous cell carcinoma Endometrial Cancer Penile cancer Cancer of the anal canal Hairy-cell leukemia Oral cancer Adrenal carcinoma Malignant melanoma Burkitt lymphoma Thyroid cancer Basal cell carcinoma Small cell lung cancer Gallbladder cancer Bladder cancer Laryngeal cancer Kaposi's sarcoma Cholangiocarcinoma Chronic lymphocytic leukemia (CLL) Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL) Malignant pleural mesothelioma Osteosarcoma Colorectal cancer	Diseases 2
Novel Novel	Symbols TP53 and VRK1	Name 1 tumor protein p53	Name2 VRK serine/threonine kinase 1	Pathway 1 Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PI5P Regulates TP53 Acetylation G2/M DNA damage checkpoint G2/M Checkpoints Stabilization of p53 Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional Regulation by VENTX RUNX3 regulates CDKN1A transcription Regulation of PTEN gene transcription Regulation of PTEN gene transcription Loss of function of TP53 in cancer due to loss of tetramerization ability Signaling by ALK fusions and activated point mutants Regulation of NF-kappa B signaling Zygotic genome activation (ZGA) Factors involved in megakaryocyte development and platelet production PKR-mediated signaling	Pathway 2 Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation	Drugs 1 Acetylsalicylic acid Zinc Triethyl phosphate AZD 3355 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1 Chronic myeloid leukemia (CML) Breast cancer Non-small cell lung cancer Gastric cancer Adult T-cell leukemia Choriocarcinoma Esophageal cancer Glioma Pancreatic cancer Vulvar cancer Multiple myeloma Choroid plexus papilloma Ovarian cancer Hepatocellular carcinoma Squamous cell carcinoma Endometrial Cancer Penile cancer Cancer of the anal canal Hairy-cell leukemia Oral cancer Adrenal carcinoma Malignant melanoma Burkitt lymphoma Thyroid cancer Basal cell carcinoma Small cell lung cancer Gallbladder cancer Bladder cancer Laryngeal cancer Kaposi's sarcoma Cholangiocarcinoma Chronic lymphocytic leukemia (CLL) Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL) Malignant pleural mesothelioma Osteosarcoma Colorectal cancer	Diseases 2 Pontocerebellar hypoplasia
Novel Novel	Symbols TP53 and HECW1	Name 1 tumor protein p53	Name2 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1	Pathway 1 Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PI5P Regulates TP53 Acetylation G2/M DNA damage checkpoint G2/M Checkpoints Stabilization of p53 Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional Regulation by VENTX RUNX3 regulates CDKN1A transcription Regulation of PTEN gene transcription Regulation of PTEN gene transcription Loss of function of TP53 in cancer due to loss of tetramerization ability Signaling by ALK fusions and activated point mutants Regulation of NF-kappa B signaling Zygotic genome activation (ZGA) Factors involved in megakaryocyte development and platelet production PKR-mediated signaling	Pathway 2 Degradation of DVL	Drugs 1 Acetylsalicylic acid Zinc Triethyl phosphate AZD 3355 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1 Chronic myeloid leukemia (CML) Breast cancer Non-small cell lung cancer Gastric cancer Adult T-cell leukemia Choriocarcinoma Esophageal cancer Glioma Pancreatic cancer Vulvar cancer Multiple myeloma Choroid plexus papilloma Ovarian cancer Hepatocellular carcinoma Squamous cell carcinoma Endometrial Cancer Penile cancer Cancer of the anal canal Hairy-cell leukemia Oral cancer Adrenal carcinoma Malignant melanoma Burkitt lymphoma Thyroid cancer Basal cell carcinoma Small cell lung cancer Gallbladder cancer Bladder cancer Laryngeal cancer Kaposi's sarcoma Cholangiocarcinoma Chronic lymphocytic leukemia (CLL) Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL) Malignant pleural mesothelioma Osteosarcoma Colorectal cancer	Diseases 2
Novel Novel	Symbols TP53 and NABP1	Name 1 tumor protein p53	Name2 nucleic acid binding protein 1	Pathway 1 Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PI5P Regulates TP53 Acetylation G2/M DNA damage checkpoint G2/M Checkpoints Stabilization of p53 Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional Regulation by VENTX RUNX3 regulates CDKN1A transcription Regulation of PTEN gene transcription Regulation of PTEN gene transcription Loss of function of TP53 in cancer due to loss of tetramerization ability Signaling by ALK fusions and activated point mutants Regulation of NF-kappa B signaling Zygotic genome activation (ZGA) Factors involved in megakaryocyte development and platelet production PKR-mediated signaling	Pathway 2 RNA polymerase II transcribes snRNA genes RNA polymerase II transcribes snRNA genes	Drugs 1 Acetylsalicylic acid Zinc Triethyl phosphate AZD 3355 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1 Chronic myeloid leukemia (CML) Breast cancer Non-small cell lung cancer Gastric cancer Adult T-cell leukemia Choriocarcinoma Esophageal cancer Glioma Pancreatic cancer Vulvar cancer Multiple myeloma Choroid plexus papilloma Ovarian cancer Hepatocellular carcinoma Squamous cell carcinoma Endometrial Cancer Penile cancer Cancer of the anal canal Hairy-cell leukemia Oral cancer Adrenal carcinoma Malignant melanoma Burkitt lymphoma Thyroid cancer Basal cell carcinoma Small cell lung cancer Gallbladder cancer Bladder cancer Laryngeal cancer Kaposi's sarcoma Cholangiocarcinoma Chronic lymphocytic leukemia (CLL) Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL) Malignant pleural mesothelioma Osteosarcoma Colorectal cancer	Diseases 2
Novel Novel	Symbols TP53 and SLC9A9	Name 1 tumor protein p53	Name2 solute carrier family 9 member A9	Pathway 1 Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PI5P Regulates TP53 Acetylation G2/M DNA damage checkpoint G2/M Checkpoints Stabilization of p53 Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional Regulation by VENTX RUNX3 regulates CDKN1A transcription Regulation of PTEN gene transcription Regulation of PTEN gene transcription Loss of function of TP53 in cancer due to loss of tetramerization ability Signaling by ALK fusions and activated point mutants Regulation of NF-kappa B signaling Zygotic genome activation (ZGA) Factors involved in megakaryocyte development and platelet production PKR-mediated signaling	Pathway 2 Sodium/Proton exchangers Defective SLC9A9 causes autism 16 (AUTS16)	Drugs 1 Acetylsalicylic acid Zinc Triethyl phosphate AZD 3355 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1 Chronic myeloid leukemia (CML) Breast cancer Non-small cell lung cancer Gastric cancer Adult T-cell leukemia Choriocarcinoma Esophageal cancer Glioma Pancreatic cancer Vulvar cancer Multiple myeloma Choroid plexus papilloma Ovarian cancer Hepatocellular carcinoma Squamous cell carcinoma Endometrial Cancer Penile cancer Cancer of the anal canal Hairy-cell leukemia Oral cancer Adrenal carcinoma Malignant melanoma Burkitt lymphoma Thyroid cancer Basal cell carcinoma Small cell lung cancer Gallbladder cancer Bladder cancer Laryngeal cancer Kaposi's sarcoma Cholangiocarcinoma Chronic lymphocytic leukemia (CLL) Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL) Malignant pleural mesothelioma Osteosarcoma Colorectal cancer	Diseases 2
Novel Novel	Symbols TP53 and DCST1	Name 1 tumor protein p53	Name2 DC-STAMP domain containing 1	Pathway 1 Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PI5P Regulates TP53 Acetylation G2/M DNA damage checkpoint G2/M Checkpoints Stabilization of p53 Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional Regulation by VENTX RUNX3 regulates CDKN1A transcription Regulation of PTEN gene transcription Regulation of PTEN gene transcription Loss of function of TP53 in cancer due to loss of tetramerization ability Signaling by ALK fusions and activated point mutants Regulation of NF-kappa B signaling Zygotic genome activation (ZGA) Factors involved in megakaryocyte development and platelet production PKR-mediated signaling	Pathway 2	Drugs 1 Acetylsalicylic acid Zinc Triethyl phosphate AZD 3355 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1 Chronic myeloid leukemia (CML) Breast cancer Non-small cell lung cancer Gastric cancer Adult T-cell leukemia Choriocarcinoma Esophageal cancer Glioma Pancreatic cancer Vulvar cancer Multiple myeloma Choroid plexus papilloma Ovarian cancer Hepatocellular carcinoma Squamous cell carcinoma Endometrial Cancer Penile cancer Cancer of the anal canal Hairy-cell leukemia Oral cancer Adrenal carcinoma Malignant melanoma Burkitt lymphoma Thyroid cancer Basal cell carcinoma Small cell lung cancer Gallbladder cancer Bladder cancer Laryngeal cancer Kaposi's sarcoma Cholangiocarcinoma Chronic lymphocytic leukemia (CLL) Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL) Malignant pleural mesothelioma Osteosarcoma Colorectal cancer	Diseases 2
Novel Novel	Symbols KDR and VEGFC	Name 1 kinase insert domain receptor	Name2 vascular endothelial growth factor C	Pathway 1 Neurophilin interactions with VEGF and VEGFR VEGF binds to VEGFR leading to receptor dimerization Integrin cell surface interactions VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway VEGFR2 mediated cell proliferation Signaling by membrane-tethered fusions of PDGFRA or PDGFRB High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Pathway 2 Platelet degranulation VEGF ligand-receptor interactions VEGF binds to VEGFR leading to receptor dimerization	Drugs 1 Sorafenib Sunitinib 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea Cediranib Vatalanib XL999 TG-100801 XL820 CYC116 Ramucirumab Pegdinetanib RAF-265 Linifanib IMC-1C11 Semaxanib Pazopanib Midostaurin Axitinib 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine Cabozantinib Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Fostamatinib Erdafitinib Foretinib Ripretinib Pralsetinib Olinvacimab	Drugs 2	Diseases 1	Diseases 2 Gastric cancer
Novel Novel	Symbols CDH1 and UCA1	Name 1 cadherin 1	Name2 urothelial cancer associated 1	Pathway 1 Degradation of the extracellular matrix Degradation of the extracellular matrix Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Integrin cell surface interactions Apoptotic cleavage of cell adhesion proteins Adherens junctions interactions RHO GTPases activate IQGAPs InlA-mediated entry of Listeria monocytogenes into host cells Regulation of CDH1 Function Regulation of CDH1 mRNA translation by microRNAs Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Formation of definitive endoderm Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Penile cancer Breast cancer Gastric cancer Nasopharyngeal cancer Hepatocellular carcinoma Thyroid cancer	Diseases 2
Novel Novel	Symbols CDH1 and RRM2	Name 1 cadherin 1	Name2 ribonucleotide reductase regulatory subunit M2	Pathway 1 Degradation of the extracellular matrix Degradation of the extracellular matrix Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Integrin cell surface interactions Apoptotic cleavage of cell adhesion proteins Adherens junctions interactions RHO GTPases activate IQGAPs InlA-mediated entry of Listeria monocytogenes into host cells Regulation of CDH1 Function Regulation of CDH1 mRNA translation by microRNAs Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Formation of definitive endoderm Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Pathway 2 Interconversion of nucleotide di- and triphosphates G1/S-Specific Transcription Transcriptional Regulation by E2F6	Drugs 1	Drugs 2 Cladribine Imexon Gallium nitrate Motexafin gadolinium GTI 2040	Diseases 1 Penile cancer Breast cancer Gastric cancer Nasopharyngeal cancer Hepatocellular carcinoma Thyroid cancer	Diseases 2
Novel Novel	Symbols BIN1 and ITGA1	Name 1 bridging integrator 1	Name2 integrin subunit alpha 1	Pathway 1 Clathrin-mediated endocytosis	Pathway 2 Integrin cell surface interactions Integrin cell surface interactions Laminin interactions Other semaphorin interactions Smooth Muscle Contraction CHL1 interactions Platelet Adhesion to exposed collagen	Drugs 1	Drugs 2	Diseases 1 Centronuclear myopathy	Diseases 2
Novel Novel	Symbols BIN1 and CLIP1	Name 1 bridging integrator 1	Name2 CAP-Gly domain containing linker protein 1	Pathway 1 Clathrin-mediated endocytosis	Pathway 2 Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion RHO GTPases activate IQGAPs RHO GTPases Activate Formins Mitotic Prometaphase EML4 and NUDC in mitotic spindle formation Signaling by LTK in cancer	Drugs 1	Drugs 2	Diseases 1 Centronuclear myopathy	Diseases 2
Novel Novel	Symbols BIN1 and FBP1	Name 1 bridging integrator 1	Name2 fructose-bisphosphatase 1	Pathway 1 Clathrin-mediated endocytosis	Pathway 2 Gluconeogenesis	Drugs 1	Drugs 2 Adenosine phosphate 2,5-Anhydroglucitol-1,6-Biphosphate {4-[3-(6,7-Diethoxy-Quinazolin-4-Ylamino)-Phenyl]-Thiazol-2-Yl}-Methanol Mdl-29951 Fructose-6-phosphate MB-07803 Managlinat dialanetil N-[7-(3-AMINOPHENYL)-5-METHOXY-1,3-BENZOXAZOL-2-YL]-2,5-DICHLOROBENZENESULFONAMIDE 2,5-DICHLORO-N-(5-CHLORO-1,3-BENZOXAZOL-2-YL)BENZENESULFONAMIDE 2,5-DICHLORO-N-[5-METHOXY-7-(6-METHOXYPYRIDIN-3-YL)-1,3-BENZOXAZOL-2-YL]BENZENESULFONAMIDE 4-AMINO-N-[(2-SULFANYLETHYL)CARBAMOYL]BENZENESULFONAMIDE	Diseases 1 Centronuclear myopathy	Diseases 2 Fructose-1,6-bisphosphatase deficiency
Novel Novel	Symbols BIN1 and PTGER4	Name 1 bridging integrator 1	Name2 prostaglandin E receptor 4	Pathway 1 Clathrin-mediated endocytosis	Pathway 2 Prostanoid ligand receptors G alpha (s) signalling events	Drugs 1	Drugs 2 Dinoprostone Misoprostol Trichostatin A Limaprost Castor oil Grapiprant Rivenprost Rivenprost	Diseases 1 Centronuclear myopathy	Diseases 2
Novel Novel	Symbols VHL and PIWIL4	Name 1 von Hippel-Lindau tumor suppressor	Name2 piwi like RNA-mediated gene silencing 4	Pathway 1 Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha SUMOylation of ubiquitinylation proteins Neddylation Replication of the SARS-CoV-1 genome Replication of the SARS-CoV-2 genome RHOBTB3 ATPase cycle Antigen processing: Ubiquitination & Proteasome degradation	Pathway 2 PIWI-interacting RNA (piRNA) biogenesis Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)	Drugs 1	Drugs 2	Diseases 1 von Hippel-Lindau syndrome Congenital polycythemia; Familial erythrocytosis (ECYT) Renal cell carcinoma	Diseases 2
Novel	Symbols HRAS and ANAPC1	Name 1 HRas proto-oncogene, GTPase	Name2 anaphase promoting complex subunit 1	Pathway 1 SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth EPHB-mediated forward signaling Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2 Inactivation of APC/C via direct inhibition of the APC/C complex APC/C:Cdc20 mediated degradation of Cyclin B Autodegradation of Cdh1 by Cdh1:APC/C APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase APC/C:Cdc20 mediated degradation of mitotic proteins Phosphorylation of the APC/C APC-Cdc20 mediated degradation of Nek2A Separation of Sister Chromatids Senescence-Associated Secretory Phenotype (SASP) Assembly of the pre-replicative complex CDK-mediated phosphorylation and removal of Cdc6 Transcriptional Regulation by VENTX Aberrant regulation of mitotic exit in cancer due to RB1 defects Antigen processing: Ubiquitination & Proteasome degradation	Drugs 1 Hexane-1,6-Diol Trifluoroethanol Guanosine-5'-Triphosphate Guanosine-5'-Diphosphate N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE Ursolic acid	Drugs 2	Diseases 1 Penile cancer Cervical cancer Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Hepatocellular carcinoma Thyroid cancer Squamous cell carcinoma Bladder cancer	Diseases 2
Novel	Symbols HRAS and RASGRP1	Name 1 HRas proto-oncogene, GTPase	Name2 RAS guanyl releasing protein 1	Pathway 1 SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth EPHB-mediated forward signaling Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2 Effects of PIP2 hydrolysis Activation of RAS in B cells Activation of RAS in B cells FCERI mediated NF-kB activation Integrin signaling Rap1 signalling RAF/MAP kinase cascade	Drugs 1 Hexane-1,6-Diol Trifluoroethanol Guanosine-5'-Triphosphate Guanosine-5'-Diphosphate N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE Ursolic acid	Drugs 2	Diseases 1 Penile cancer Cervical cancer Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Hepatocellular carcinoma Thyroid cancer Squamous cell carcinoma Bladder cancer	Diseases 2
Novel	Symbols HRAS and TLR9	Name 1 HRas proto-oncogene, GTPase	Name2 toll like receptor 9	Pathway 1 SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth EPHB-mediated forward signaling Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2 PI3K Cascade Trafficking and processing of endosomal TLR Toll Like Receptor 9 (TLR9) Cascade Potential therapeutics for SARS TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation MyD88 dependent cascade initiated on endosome	Drugs 1 Hexane-1,6-Diol Trifluoroethanol Guanosine-5'-Triphosphate Guanosine-5'-Diphosphate N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE Ursolic acid	Drugs 2 Chloroquine Hydroxychloroquine ISS-1018 Golotimod CPG 10101 Tilsotolimod	Diseases 1 Penile cancer Cervical cancer Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Hepatocellular carcinoma Thyroid cancer Squamous cell carcinoma Bladder cancer	Diseases 2
Novel	Symbols KRAS and SOX4	Name 1 KRAS proto-oncogene, GTPase	Name2 SRY-box transcription factor 4	Pathway 1 Signaling by moderate kinase activity BRAF mutants Paradoxical activation of RAF signaling by kinase inactive BRAF RUNX3 regulates p14-ARF RAS processing Signaling downstream of RAS mutants Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2 Deactivation of the beta-catenin transactivating complex	Drugs 1 [(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID Farnesyl diphosphate Adagrasib Sotorasib	Drugs 2	Diseases 1 Acute myeloid leukemia (AML) Oral cancer Non-small cell lung cancer Multiple myeloma Cervical cancer Kaposi's sarcoma Cholangiocarcinoma Gallbladder cancer Gastric cancer Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Ovarian cancer Hepatocellular carcinoma Thyroid cancer Squamous cell carcinoma Colorectal cancer Endometrial Cancer Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Pancreatic cancer	Diseases 2
Novel	Symbols TGFBR1 and KLHL1	Name 1 transforming growth factor beta receptor 1	Name2 kelch like family member 1	Pathway 1 Downregulation of TGF-beta receptor signaling Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) SMAD2/3 Phosphorylation Motif Mutants in Cancer TGFBR2 Kinase Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer TGFBR1 LBD Mutants in Cancer UCH proteinases Ub-specific processing proteases TGFBR3 regulates TGF-beta signaling	Pathway 2	Drugs 1 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline Naphthyridine Inhibitor 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine Fostamatinib	Drugs 2	Diseases 1 Loeys-Dietz syndrome (LDS) Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)	Diseases 2
Novel	Symbols TGFBR1 and DCAF12	Name 1 transforming growth factor beta receptor 1	Name2 DDB1 and CUL4 associated factor 12	Pathway 1 Downregulation of TGF-beta receptor signaling Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) SMAD2/3 Phosphorylation Motif Mutants in Cancer TGFBR2 Kinase Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer TGFBR1 LBD Mutants in Cancer UCH proteinases Ub-specific processing proteases TGFBR3 regulates TGF-beta signaling	Pathway 2	Drugs 1 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline Naphthyridine Inhibitor 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine Fostamatinib	Drugs 2	Diseases 1 Loeys-Dietz syndrome (LDS) Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)	Diseases 2
Novel	Symbols TP53 and TAF1C	Name 1 tumor protein p53	Name2 TATA-box binding protein associated factor, RNA polymerase I subunit C	Pathway 1 Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PI5P Regulates TP53 Acetylation G2/M DNA damage checkpoint G2/M Checkpoints Stabilization of p53 Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional Regulation by VENTX RUNX3 regulates CDKN1A transcription Regulation of PTEN gene transcription Regulation of PTEN gene transcription Loss of function of TP53 in cancer due to loss of tetramerization ability Signaling by ALK fusions and activated point mutants Regulation of NF-kappa B signaling Zygotic genome activation (ZGA) Factors involved in megakaryocyte development and platelet production PKR-mediated signaling	Pathway 2 SIRT1 negatively regulates rRNA expression NoRC negatively regulates rRNA expression B-WICH complex positively regulates rRNA expression RNA Polymerase I Transcription Initiation RNA Polymerase I Transcription Initiation RNA Polymerase I Promoter Escape RNA Polymerase I Transcription Termination	Drugs 1 Acetylsalicylic acid Zinc Triethyl phosphate AZD 3355 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1 Chronic myeloid leukemia (CML) Breast cancer Non-small cell lung cancer Gastric cancer Adult T-cell leukemia Choriocarcinoma Esophageal cancer Glioma Pancreatic cancer Vulvar cancer Multiple myeloma Choroid plexus papilloma Ovarian cancer Hepatocellular carcinoma Squamous cell carcinoma Endometrial Cancer Penile cancer Cancer of the anal canal Hairy-cell leukemia Oral cancer Adrenal carcinoma Malignant melanoma Burkitt lymphoma Thyroid cancer Basal cell carcinoma Small cell lung cancer Gallbladder cancer Bladder cancer Laryngeal cancer Kaposi's sarcoma Cholangiocarcinoma Chronic lymphocytic leukemia (CLL) Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL) Malignant pleural mesothelioma Osteosarcoma Colorectal cancer	Diseases 2
Novel	Symbols TP53 and VRK1	Name 1 tumor protein p53	Name2 VRK serine/threonine kinase 1	Pathway 1 Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PI5P Regulates TP53 Acetylation G2/M DNA damage checkpoint G2/M Checkpoints Stabilization of p53 Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional Regulation by VENTX RUNX3 regulates CDKN1A transcription Regulation of PTEN gene transcription Regulation of PTEN gene transcription Loss of function of TP53 in cancer due to loss of tetramerization ability Signaling by ALK fusions and activated point mutants Regulation of NF-kappa B signaling Zygotic genome activation (ZGA) Factors involved in megakaryocyte development and platelet production PKR-mediated signaling	Pathway 2 Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation	Drugs 1 Acetylsalicylic acid Zinc Triethyl phosphate AZD 3355 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1 Chronic myeloid leukemia (CML) Breast cancer Non-small cell lung cancer Gastric cancer Adult T-cell leukemia Choriocarcinoma Esophageal cancer Glioma Pancreatic cancer Vulvar cancer Multiple myeloma Choroid plexus papilloma Ovarian cancer Hepatocellular carcinoma Squamous cell carcinoma Endometrial Cancer Penile cancer Cancer of the anal canal Hairy-cell leukemia Oral cancer Adrenal carcinoma Malignant melanoma Burkitt lymphoma Thyroid cancer Basal cell carcinoma Small cell lung cancer Gallbladder cancer Bladder cancer Laryngeal cancer Kaposi's sarcoma Cholangiocarcinoma Chronic lymphocytic leukemia (CLL) Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL) Malignant pleural mesothelioma Osteosarcoma Colorectal cancer	Diseases 2 Pontocerebellar hypoplasia
Novel	Symbols TP53 and HECW1	Name 1 tumor protein p53	Name2 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1	Pathway 1 Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PI5P Regulates TP53 Acetylation G2/M DNA damage checkpoint G2/M Checkpoints Stabilization of p53 Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional Regulation by VENTX RUNX3 regulates CDKN1A transcription Regulation of PTEN gene transcription Regulation of PTEN gene transcription Loss of function of TP53 in cancer due to loss of tetramerization ability Signaling by ALK fusions and activated point mutants Regulation of NF-kappa B signaling Zygotic genome activation (ZGA) Factors involved in megakaryocyte development and platelet production PKR-mediated signaling	Pathway 2 Degradation of DVL	Drugs 1 Acetylsalicylic acid Zinc Triethyl phosphate AZD 3355 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1 Chronic myeloid leukemia (CML) Breast cancer Non-small cell lung cancer Gastric cancer Adult T-cell leukemia Choriocarcinoma Esophageal cancer Glioma Pancreatic cancer Vulvar cancer Multiple myeloma Choroid plexus papilloma Ovarian cancer Hepatocellular carcinoma Squamous cell carcinoma Endometrial Cancer Penile cancer Cancer of the anal canal Hairy-cell leukemia Oral cancer Adrenal carcinoma Malignant melanoma Burkitt lymphoma Thyroid cancer Basal cell carcinoma Small cell lung cancer Gallbladder cancer Bladder cancer Laryngeal cancer Kaposi's sarcoma Cholangiocarcinoma Chronic lymphocytic leukemia (CLL) Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL) Malignant pleural mesothelioma Osteosarcoma Colorectal cancer	Diseases 2
Novel	Symbols TP53 and NABP1	Name 1 tumor protein p53	Name2 nucleic acid binding protein 1	Pathway 1 Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PI5P Regulates TP53 Acetylation G2/M DNA damage checkpoint G2/M Checkpoints Stabilization of p53 Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional Regulation by VENTX RUNX3 regulates CDKN1A transcription Regulation of PTEN gene transcription Regulation of PTEN gene transcription Loss of function of TP53 in cancer due to loss of tetramerization ability Signaling by ALK fusions and activated point mutants Regulation of NF-kappa B signaling Zygotic genome activation (ZGA) Factors involved in megakaryocyte development and platelet production PKR-mediated signaling	Pathway 2 RNA polymerase II transcribes snRNA genes RNA polymerase II transcribes snRNA genes	Drugs 1 Acetylsalicylic acid Zinc Triethyl phosphate AZD 3355 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1 Chronic myeloid leukemia (CML) Breast cancer Non-small cell lung cancer Gastric cancer Adult T-cell leukemia Choriocarcinoma Esophageal cancer Glioma Pancreatic cancer Vulvar cancer Multiple myeloma Choroid plexus papilloma Ovarian cancer Hepatocellular carcinoma Squamous cell carcinoma Endometrial Cancer Penile cancer Cancer of the anal canal Hairy-cell leukemia Oral cancer Adrenal carcinoma Malignant melanoma Burkitt lymphoma Thyroid cancer Basal cell carcinoma Small cell lung cancer Gallbladder cancer Bladder cancer Laryngeal cancer Kaposi's sarcoma Cholangiocarcinoma Chronic lymphocytic leukemia (CLL) Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL) Malignant pleural mesothelioma Osteosarcoma Colorectal cancer	Diseases 2
Novel	Symbols TP53 and SLC9A9	Name 1 tumor protein p53	Name2 solute carrier family 9 member A9	Pathway 1 Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PI5P Regulates TP53 Acetylation G2/M DNA damage checkpoint G2/M Checkpoints Stabilization of p53 Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional Regulation by VENTX RUNX3 regulates CDKN1A transcription Regulation of PTEN gene transcription Regulation of PTEN gene transcription Loss of function of TP53 in cancer due to loss of tetramerization ability Signaling by ALK fusions and activated point mutants Regulation of NF-kappa B signaling Zygotic genome activation (ZGA) Factors involved in megakaryocyte development and platelet production PKR-mediated signaling	Pathway 2 Sodium/Proton exchangers Defective SLC9A9 causes autism 16 (AUTS16)	Drugs 1 Acetylsalicylic acid Zinc Triethyl phosphate AZD 3355 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1 Chronic myeloid leukemia (CML) Breast cancer Non-small cell lung cancer Gastric cancer Adult T-cell leukemia Choriocarcinoma Esophageal cancer Glioma Pancreatic cancer Vulvar cancer Multiple myeloma Choroid plexus papilloma Ovarian cancer Hepatocellular carcinoma Squamous cell carcinoma Endometrial Cancer Penile cancer Cancer of the anal canal Hairy-cell leukemia Oral cancer Adrenal carcinoma Malignant melanoma Burkitt lymphoma Thyroid cancer Basal cell carcinoma Small cell lung cancer Gallbladder cancer Bladder cancer Laryngeal cancer Kaposi's sarcoma Cholangiocarcinoma Chronic lymphocytic leukemia (CLL) Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL) Malignant pleural mesothelioma Osteosarcoma Colorectal cancer	Diseases 2
Novel	Symbols TP53 and DCST1	Name 1 tumor protein p53	Name2 DC-STAMP domain containing 1	Pathway 1 Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ub-specific processing proteases Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation PI5P Regulates TP53 Acetylation G2/M DNA damage checkpoint G2/M Checkpoints Stabilization of p53 Transcriptional activation of cell cycle inhibitor p21 The role of GTSE1 in G2/M progression after G2 checkpoint Transcriptional Regulation by VENTX RUNX3 regulates CDKN1A transcription Regulation of PTEN gene transcription Regulation of PTEN gene transcription Loss of function of TP53 in cancer due to loss of tetramerization ability Signaling by ALK fusions and activated point mutants Regulation of NF-kappa B signaling Zygotic genome activation (ZGA) Factors involved in megakaryocyte development and platelet production PKR-mediated signaling	Pathway 2	Drugs 1 Acetylsalicylic acid Zinc Triethyl phosphate AZD 3355 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Drugs 2	Diseases 1 Chronic myeloid leukemia (CML) Breast cancer Non-small cell lung cancer Gastric cancer Adult T-cell leukemia Choriocarcinoma Esophageal cancer Glioma Pancreatic cancer Vulvar cancer Multiple myeloma Choroid plexus papilloma Ovarian cancer Hepatocellular carcinoma Squamous cell carcinoma Endometrial Cancer Penile cancer Cancer of the anal canal Hairy-cell leukemia Oral cancer Adrenal carcinoma Malignant melanoma Burkitt lymphoma Thyroid cancer Basal cell carcinoma Small cell lung cancer Gallbladder cancer Bladder cancer Laryngeal cancer Kaposi's sarcoma Cholangiocarcinoma Chronic lymphocytic leukemia (CLL) Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL) Malignant pleural mesothelioma Osteosarcoma Colorectal cancer	Diseases 2
Novel	Symbols KDR and VEGFC	Name 1 kinase insert domain receptor	Name2 vascular endothelial growth factor C	Pathway 1 Neurophilin interactions with VEGF and VEGFR VEGF binds to VEGFR leading to receptor dimerization Integrin cell surface interactions VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway VEGFR2 mediated cell proliferation Signaling by membrane-tethered fusions of PDGFRA or PDGFRB High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Pathway 2 Platelet degranulation VEGF ligand-receptor interactions VEGF binds to VEGFR leading to receptor dimerization	Drugs 1 Sorafenib Sunitinib 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea Cediranib Vatalanib XL999 TG-100801 XL820 CYC116 Ramucirumab Pegdinetanib RAF-265 Linifanib IMC-1C11 Semaxanib Pazopanib Midostaurin Axitinib 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine Cabozantinib Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Fostamatinib Erdafitinib Foretinib Ripretinib Pralsetinib Olinvacimab	Drugs 2	Diseases 1	Diseases 2 Gastric cancer
Novel	Symbols CDH1 and UCA1	Name 1 cadherin 1	Name2 urothelial cancer associated 1	Pathway 1 Degradation of the extracellular matrix Degradation of the extracellular matrix Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Integrin cell surface interactions Apoptotic cleavage of cell adhesion proteins Adherens junctions interactions RHO GTPases activate IQGAPs InlA-mediated entry of Listeria monocytogenes into host cells Regulation of CDH1 Function Regulation of CDH1 mRNA translation by microRNAs Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Formation of definitive endoderm Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Penile cancer Breast cancer Gastric cancer Nasopharyngeal cancer Hepatocellular carcinoma Thyroid cancer	Diseases 2
Novel	Symbols CDH1 and RRM2	Name 1 cadherin 1	Name2 ribonucleotide reductase regulatory subunit M2	Pathway 1 Degradation of the extracellular matrix Degradation of the extracellular matrix Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Integrin cell surface interactions Apoptotic cleavage of cell adhesion proteins Adherens junctions interactions RHO GTPases activate IQGAPs InlA-mediated entry of Listeria monocytogenes into host cells Regulation of CDH1 Function Regulation of CDH1 mRNA translation by microRNAs Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Formation of definitive endoderm Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Pathway 2 Interconversion of nucleotide di- and triphosphates G1/S-Specific Transcription Transcriptional Regulation by E2F6	Drugs 1	Drugs 2 Cladribine Imexon Gallium nitrate Motexafin gadolinium GTI 2040	Diseases 1 Penile cancer Breast cancer Gastric cancer Nasopharyngeal cancer Hepatocellular carcinoma Thyroid cancer	Diseases 2
Novel	Symbols BIN1 and ITGA1	Name 1 bridging integrator 1	Name2 integrin subunit alpha 1	Pathway 1 Clathrin-mediated endocytosis	Pathway 2 Integrin cell surface interactions Integrin cell surface interactions Laminin interactions Other semaphorin interactions Smooth Muscle Contraction CHL1 interactions Platelet Adhesion to exposed collagen	Drugs 1	Drugs 2	Diseases 1 Centronuclear myopathy	Diseases 2
Novel	Symbols BIN1 and CLIP1	Name 1 bridging integrator 1	Name2 CAP-Gly domain containing linker protein 1	Pathway 1 Clathrin-mediated endocytosis	Pathway 2 Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion RHO GTPases activate IQGAPs RHO GTPases Activate Formins Mitotic Prometaphase EML4 and NUDC in mitotic spindle formation Signaling by LTK in cancer	Drugs 1	Drugs 2	Diseases 1 Centronuclear myopathy	Diseases 2
Novel	Symbols BIN1 and FBP1	Name 1 bridging integrator 1	Name2 fructose-bisphosphatase 1	Pathway 1 Clathrin-mediated endocytosis	Pathway 2 Gluconeogenesis	Drugs 1	Drugs 2 Adenosine phosphate 2,5-Anhydroglucitol-1,6-Biphosphate {4-[3-(6,7-Diethoxy-Quinazolin-4-Ylamino)-Phenyl]-Thiazol-2-Yl}-Methanol Mdl-29951 Fructose-6-phosphate MB-07803 Managlinat dialanetil N-[7-(3-AMINOPHENYL)-5-METHOXY-1,3-BENZOXAZOL-2-YL]-2,5-DICHLOROBENZENESULFONAMIDE 2,5-DICHLORO-N-(5-CHLORO-1,3-BENZOXAZOL-2-YL)BENZENESULFONAMIDE 2,5-DICHLORO-N-[5-METHOXY-7-(6-METHOXYPYRIDIN-3-YL)-1,3-BENZOXAZOL-2-YL]BENZENESULFONAMIDE 4-AMINO-N-[(2-SULFANYLETHYL)CARBAMOYL]BENZENESULFONAMIDE	Diseases 1 Centronuclear myopathy	Diseases 2 Fructose-1,6-bisphosphatase deficiency
Novel	Symbols BIN1 and PTGER4	Name 1 bridging integrator 1	Name2 prostaglandin E receptor 4	Pathway 1 Clathrin-mediated endocytosis	Pathway 2 Prostanoid ligand receptors G alpha (s) signalling events	Drugs 1	Drugs 2 Dinoprostone Misoprostol Trichostatin A Limaprost Castor oil Grapiprant Rivenprost Rivenprost	Diseases 1 Centronuclear myopathy	Diseases 2
Novel	Symbols VHL and PIWIL4	Name 1 von Hippel-Lindau tumor suppressor	Name2 piwi like RNA-mediated gene silencing 4	Pathway 1 Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha SUMOylation of ubiquitinylation proteins Neddylation Replication of the SARS-CoV-1 genome Replication of the SARS-CoV-2 genome RHOBTB3 ATPase cycle Antigen processing: Ubiquitination & Proteasome degradation	Pathway 2 PIWI-interacting RNA (piRNA) biogenesis Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)	Drugs 1	Drugs 2	Diseases 1 von Hippel-Lindau syndrome Congenital polycythemia; Familial erythrocytosis (ECYT) Renal cell carcinoma	Diseases 2

Page 46 out of 98 pages

Search Results : Cancer